Physician profile
Robert Yu
NPI 1992004600
$5,887.99
in general payments reported to CMS, 2019-2025
20 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,008 · 2021: $198 · 2022: $480 · 2023: $312 · 2024: $1,367 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283 · Travel and Lodging: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.49 |
| Travel and Lodging | $919.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,582.33 | 2019 | |
| Medtronic, INC. | $1,084.88 | 2024 | Interstim, Ligasure, Signia |
| Ethicon US, LLC | $395.26 | 2021-2025 | Enseal X1, Dermabond Prineo, Stratafix |
| Integra Lifesciences Corporation | $357.32 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Stryker Corporation | $256.86 | 2019-2024 | 1788 |
| Activ Surgical, INC. | $187.39 | 2022-2023 | Activsight |
| Abbvie INC. | $165.35 | 2021-2025 | |
| Boston Scientific Corporation | $121.34 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $118.79 | 2019 | |
| Shire North American Group INC | $118.73 | 2019 | |
| Cook Biotech Incorporated | $110.65 | 2023 | Biodesign |
| Conmed Corporation | $85.72 | 2025 | Airseal |
| Cook Medical LLC | $67.50 | 2025 | Hemospray |
| Thd America, INC. | $65.84 | 2023-2025 | |
| Reprise Biomedical, INC. | $42.36 | 2025 | Miro3d |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $39.31 | 2022-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $36.91 | 2025 | Gattex, Entyvio |
| Mallinckrodt Hospital Products INC. | $20.37 | 2024 | Terlivaz |
| Qol Medical, LLC | $17.03 | 2023 | Sucraid |
| Organon LLC | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.